We create value and contribute to improved quality of life in Life Science

2

Sales and EBITDA rolling 12 months by quarter

The Group's net sales LTM (MSEK)

excluding one-time effects

1 320

1 229

1 220

1 120

1 111

1 046

1 007

1 020

956

916

920

858

885

820

720

620

21Q2

21Q3

21Q4

22Q1

22Q2

22Q3

22Q4

23Q1

21% Sales growth in 2022

The Group's EBITDA and EBITA (line) LTM (MSEK)

excluding one-time effects

300

257

239

250

216

228

203

200

187

166

174

203

187

178

150

167

160

145

100

127

133

50

0

21Q2

21Q3

21Q4

22Q1

22Q2

22Q3

22Q4

23Q1

28% EBITDA growth in 2022

3

MedCap | An active investor in Life Science companies

First Quarter 2023

Sales by Business Area

Sales by Product Category

Oth Food 2%

(Nutrition...)

Sales by Market

RoW

3%

Specialty

Pharma

35%

1 229

MSEK

MedTech

65%

15%

Medical

Devices

15%

Pharma

32%

Europe

25%

Sweden

49%

Nordic

Assistive

Technology

36%

23%

4

MedCap Platforms

Assistive Technology

Diagnostic ECG

Probiotics, Nutrition

Components for

CDMO and Packaging

medical imaging

Position

Simplifying life for people

Digitalizing work-flow with

Partner for contract

Partner for carbon fiber

with special needs

easy to use ECG

manufacturing

engineering & manufact'ng

• Prevalence of e.g. Autism,

•

Cardio diagnostics

•

Wellness

•

Medical imaging

Drivers

ADHD, Dementia

•

Hospital digitalization

•

Fitness

•

Mammography

and mobility

•

and integration

Independence, accessibility,

  • Aging population

Markets

• Nordics, Netherlands, UK,

• Nordics, Germany, Europe

• Nordics

• Europe, USA

Global Exports

Exports

MedTech

MedTech

MedTech

MedTech

Pharma & CDMO

Developing and marketing specialty pharma in Nordics

  • Pharmaceutical demand in e.g. Infection; Acute care; ADHD; Substance abuse
  • Pharmaceutical shortages
  • Nordics,
    Outlicensing in Europe

Specialty Pharma

5

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

MedCap AB published this content on 29 May 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 31 May 2023 08:36:18 UTC.